Vav3 Modulates B Cell Receptor Responses by Regulating Phosphoinositide 3-Kinase Activation

Kazunori Inabe, Masamichi Ishiai, Andrew M. Scharenberg, Norman Freshney, Julian Downward, and Tomohiro Kurosaki

1Department of Molecular Genetics, Institute for Liver Research, Kansai Medical University, and 2Immune Cell Regulation Group, RIKEN Research Center for Allergy and Immunology, Moriguchi 570-8506, Japan
3Department of Pediatrics and Immunology, University of Washington, Seattle, WA 98195
4Signal Transduction Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, United Kingdom

Abstract

To elucidate the mechanism(s) by which Vav3, a new member of the Vav family proteins, participates in B cell antigen receptor (BCR) signaling, we have generated a B cell line deficient in Vav3. Here we report that Vav3 influences phosphoinositide 3-kinase (PI3K) function through Rac1 in that phosphatidylinositol-3,4,5-trisphosphate (PIP$_3$) generation was attenuated by loss of Vav3 or by expression of a dominant negative form of Rac1. The functional interaction between PI3K and Rac1 was also demonstrated by increased PI3K activity in the presence of GTP-bound Rac1. In addition, we show that defects of calcium mobilization and c-Jun N terminal kinase (JNK) activation in Vav3-deficient cells are relieved by deletion of a PIP$_3$-hydrolyzing enzyme, SH2 domain-containing inositol polyphosphate 5'-phosphatase (SHIP). Hence, our results suggest a role for Vav3 in regulating the B cell responses by promoting the sustained production of PIP$_3$ and thereby calcium flux.

Key words: Akt • calcium • gene targeting • JNK • Rac

Introduction

Stimulation of the B cell antigen receptor (BCR)* leads to the sequential activation of protein tyrosine kinases (PTKs) that phosphorylate numerous cellular proteins including Vav isoforms and phospholipase C (PLC)•γ2 (1–4). The proto-oncogene Vav (herein referred to as Vav1) was first discovered by virtue of a mutation that rendered it able to transform fibroblasts. Vav1 contains a guanine nucleotide exchange factor (GEF) domain for the Rho/Rac/Cdc42 family of small GTPases, a pleckstrin homology (PH) domain, and two src homology (SH)3 domains that flank one SH2 domain (5). In vitro studies show that the GEF activity of Vav1 is regulated by tyrosine phosphorylation (6) and by inositol lipids that interact with the Vav1 PH domain (7). However, whether this mechanism operates in vivo is still unclear.

Since Vav1 discovery, two new Vav members (Vav2 and Vav3) have been identified. Although all Vav family proteins have similar structural features, they display different expression patterns. Vav1 is primarily expressed in hematopoietic lineages (8), while Vav2 and Vav3 have a relatively broad expression profile (9–11).

Vav1 has been shown to be critical for T cell development as well as mast cell activation (12–15). Moreover, the importance of Vav1 and Vav2 proteins for B cell development and activation has been recently underscored by gene targeting and overexpression experiments. The B cell developmental and functional defects are relatively mild in mice lacking either Vav1 or Vav2, while double-deficient mice exhibit more severe defects (12, 13, 16, 17). The small numbers of peripheral B cells which can develop in the absence of both Vav1 and Vav2 display a profound defect in BCR-mediated calcium mobilization. Conversely, overexpression of either Vav1 or Vav2 in Bal-17 B cells results in an increase of BCR-mediated calcium mobilization, thereby leading to enhancement of nuclear factor of

Address correspondence to Tomohiro Kurosaki, Department of Molecular Genetics, Institute for Liver Research, Kansai Medical University, Moriguchi 570-8506, Japan. Phone: 81-6-6993-9445; Fax: 81-6-6994-6099; E-mail: kurosaki@mxr.mesh.ne.jp

*Abbreviations used in this paper: BCR, B cell antigen receptor; CRIB, Cdc42/Rac interactive binding domain; GEF, guanine nucleotide exchange factor; GEM, glycolipid-enriched microdomain; IP$_3$, inositol 1,4,5-trisphosphate; PH, pleckstrin homology; PIP$_3$, phosphoinositide 3-kinase; PIP$_5$, phosphatidylinositol-4,5-bisphosphate; PIP$_7$, phosphatidylinositol-3,4,5-trisphosphate; PLC, phospholipase C; PTK, protein tyrosine kinase; SH, src homology; SHIP, SH2 domain-containing inositol polyphosphate 5'-phosphatase.
activated T cell (NF-AT) activation (18). However, the
effect molecular mechanism(s) by which Vav1 and Vav2
participate in BCR signaling still remains to be determined.
Moreover, despite the high expression of Vav3 in periph-
ery lymphocytes and spleen cells (10, 11), the role of Vav3
in BCR signaling has not been addressed.

In this study, we first characterized BCR signaling of
DT40 B cells deficient in Vav3. Then we examined how
Vav3 exerts its functions. Vav3-deficient B cells exhibited
similar defects to those in phosphoinositide 3-kinase (PI3K)-
deficient B cells, which led us to consider the func-
tional interaction between Vav3 and PI3K. Here we show
that phosphatidylinositol-3,4,5-trisphosphate (PIP3)
generation and subsequent Akt activation are attenuated by loss
of Vav3 or by introduction of dominant negative Rac1.
Supporting the positive effect of Vav3 on PI3K, PI3K en-
yzymatic activity is upregulated by Rac1 in a GTP-depen-
dent manner. Furthermore, the defects in Vav3-deficient
cells can be suppressed by deletion of a PIP3 hydrolyzing
enzyme, SH2 domain-containing inositol polyphosphate
mAb (M4), rabbit anti-Lyn Abs, and rabbit anti-PLC-
(311–430 amino acid region), respectively. The anti-chicken IgM
chicken Vav3 (128–193 amino acid region) and chicken Vav2
were described previously (22). The following Abs were pur-
ased from Santa Cruz Biotechnology, Inc., anti-c-Jun NH-
terminal kinase 1 (JNK1) mAb from BD PharMingen, anti-T7•Tag mAb
were purchased from Cytoskeleton.

**Materials and Methods**

**Cells, Abs, and Reagents.** Various mutant chicken DT40 B
cells were cultured as described previously (19, 20). Human 293T
cells were cultured in DMEM containing 10% FCS. Preparation of
murine splenic B cells was described previously (21).

Anti-Vav3 and anti-Vav2 Abs were obtained by immunizing
rabbits with bacterially expressed GST fusion protein containing
chicken Vav3 (128–193 amino acid region) and chicken Vav2
(311–430 amino acid region), respectively. The anti-chicken IgM
mAb (M4), rabbit anti-Lyn Abs, and rabbit anti-PLC-γ2 Abs
were described previously (22). The following Abs were pur-
ased: anti-phosphotyrosine mAb (4G10), anti-Rac1 mAb, and
rabbit anti-PI3K p85 Abs from Upstate Biotechnology, goat anti-
PI3K p110α Abs (sc-1331) and goat anti-Akt1 Abs (sc-1618)
from Santa Cruz Biotechnology, Inc., anti-c-Jun NH2-terminal
kinase 1 (JNK1) mAb from BD PharMingen, anti-T7•Tag mAb
from Novagen, and goat anti-mouse IgM from Jackson Im-
unoResearch Laboratories. Recombinant GST-Rac1 proteins
were purchased from Cytoskeleton.

dNA Cloning. A chicken EST clone (GenBank/EMBL/
DDBJ accession no. AJ953753) was found by homology search of
the NCBI database using the mouse Vav3 cDNA sequences. A
AZAP DT40 cDNA library was screened by using the EST
cDNA fragment as a probe, giving rise to isolation of 26 clones.
The longest insert that contains the open reading frame encoding
846 amino acids has been deposited into GenBank (GenBank/
EMBL/DDBJ accession no. AY046915).

To isolate chicken Vav2 cDNA, a cDNA fragment encoding
human Vav2 was used as a probe for screening the AZAP DT40
cDNA library under the low-stringency conditions. 23 positive
clones were identified and further characterized. The complete
sequence of the longest insert (encoding protein of 839 amino ac-
ids) has been deposited into GenBank (GenBank/EMBL/DDBJ
accession no. AY046916).

Expression Constructs and Transfection. The chicken Vav3 GEF
mutant construct (altering amino acids 336–342 from LLLQELV
to IIIQDAA) (23) was generated by oligonucleotide-directed
mutagenesis. The cDNAs encoding wild-type Vav3, its GEF
mutant, or wild-type Vav2 were subcloned into the pApuro ex-
ression vector (24). T7-tagged Btk cDNA in the pApuro
expression vector was described previously (25). These constructs
were transfected into Vav3-deficient DT40 cells by electropora-
tion, and selected in the presence of puromycin (0.5 μg/ml). Ex-
pression of transfected cDNAs was confirmed by Western blot
analysis.

cDNAs encoding bovine p85α subunit and chicken p110α
subunit of PI3K were provided by Drs. Michael D. Waterfield
(London, UK) and Peter K. Vogt (La Jolla, CA), respectively. A
kinase-negative p110α cDNA (R916P) was generated by oli-
gonucleotide-directed mutagenesis. These cDNAs were subcloned
into the pAneo expression vector (26). 293T cells were transfected
with p85α cDNA together with either wild-type or kinase-nega-
tive p110α cDNA using calcium phosphate precipitation method.

Generation of Vav3- and PI3K p110α-deficient DT40 Cells.
DT40 genomic fragments of Vav3 and PI3K p110α were ob-
tained by PCR. The targeting vectors pVav3-brs, pVav3-hisD,
and pVav3-neo were constructed by replacing the 0.3–kb ge-
nomic DNA containing exons that encode a part of Dbl homol-
gy region (308–338 amino acids) with brs, hisD, and neo cas-
ettes, respectively. These cassettes were flanked by 2.5 kb and
6.5 kb of Vav3 genomic sequences on the 5′ and 3′ sides, respec-
tively. To isolate Vav3-deficient cells, DT40 cells transfected se-
quentially with pVav3-hisD and pVav3-brs were selected in the
presence of proper drug. DT40 cells deficient for both SHIP and
Vav3 were generated by successive transfection with pVav3-hisD
and pVav3-neo into SHIP-deficient cells (19).
The neo and hisD targeting vectors of p110α were constructed
by replacing the 0.5–kb genomic fragment containing exons cor-
responding to a part of kinase domain (831–888 amino acids)
with neo and hisD cassettes, respectively. These constructs
spanned 1.7 kb (5′ side) and 0.8 kb (3′ side) of p110α sequences.
The targeting vectors were sequentially transfected into DT40
cells to obtain a null mutant.

Selection for drug-resistance clones was performed by using
either alone or combinations of histidiol (1 mg/ml), blastcidin S
(50 μg/ml), and G418 (2 mg/ml).

**Biochemical Analyses.** For immunoprecipitation, cells were
solubilized in lysis buffer (10 mM Tris- HCl [pH 7.5], 150 mM
NaCl, and 1% Nonidet P-40) supplemented with protease and
phosphatase inhibitors as described previously (24). Preclreated ly-
sates were incubated with proper Abs and protein A-agarose. For
Western blot analysis, immunoprecipitates, affinity precipitates,
or whole-cell lysates were resolved on SDS-PAGE, transferred
to polyvinylidene difluoride (PVDF) membrane (Bio-Rad Labora-
tories), and detected by the indicated Abs and enhanced chemilu-
scence (ECL) system (Amersham Pharmacia Biotech). In
vitro kinase assays of Akt and JNK1 were performed as described
previously (27). The reaction products were resolved on SDS-
PAGE, dried, and subjected to quantification of radioactivity by
using a Fuji FLA2000 bioimaging analyzer (Fuji Photo Film).
Based on these analyses, the stimulation folds are shown in Figs. 3
E, 4 B, 5 C, 5 D, 9 B, 9 C, and 10 C.
(25 mM Hepes [pH 7.3], 150 mM NaCl, 5 mM EGTA, 20 mM β-glycerophosphate, 10 mM NaF, 2 mM sodium vanadate, 0.5% Triton X-100, 4% glycerol, 5 mM dithiothreitol, 0.5 mM PMSF, and 5 μg/ml each leupeptin and pepstatin) were incubated with the beads for 10 min at 4°C. After quick wash in the lysis buffer, bound proteins were eluted from the beads with SDS-PAGE sample buffer. Eluted samples were resolved on 12.5% SDS-PAGE and subsequently subjected to Western blot analysis using anti-Rac1 mAb.

Glycolipid-enriched microdomains (GEMs) were isolated from cell lysates in Triton X-100 and floatation on sucrose density gradients as described previously (30).

The amount of proteins detected by Western blotting was determined by scanning the autoradiography followed by processing of the data with NIH-image program. Based on these analyses, the stimulation fold changes are shown in Figs. 3 C, 4 D, 5 B, and 10 B.

Measurements of [Ca2+]i, Inositol Phosphates, and Phosphoinositides. Calcium mobilization was measured using fura-2 in a bulk spectrofluorimeter as described (30). Production of IP3 was measured using a commercial IP3 assay system (Biotrak TRK 1000; Amersham Pharmacia Biotech) as described previously (26).

Determination of phosphatidylinositol-4,5-bisphosphate (PIP2) was performed by using the Biotrak TRK 1000 assay kit according to the manufacturer’s instructions. Briefly, PIP2 extracted from the cells using methanol/chloroform/12 M HCl (80:40:1 vol/vol) was hydrolyzed into IP3 by 1 M KOH at 100°C for 15 min. Samples were neutralized and then assayed as described above.

Thin-layer chromatography (TLC) analyses of phosphoinositides were performed by 32P labeling of cells, extraction of lipids, and TLC analysis as described previously (27, 31). The radioactivity of PIP2 spots was quantified by using a Fuji FLA2000 bioimaging analyzer and was normalized to the radioactivity in phospholipids of the samples. Then, the resulting values were normalized to the value at time zero of BCR stimulation for each of three independent experiments and averaged.

PI3K Assay. PI3K activity was essentially measured as described previously with minor modifications (32). 293T cells transfected together with PI3K p85α and p110α cDNAs were solubilized in lysis buffer (20 mM Tris-HCl [pH 8.0], 137 mM NaCl, 1 mM EDTA, 0.3 mM dithiothreitol, 0.5 mM PMSF, 1% Triton X-100, and 10 μg/ml each aprotinin and leupeptin), and PI3K was immunoprecipitated with anti-p85 Abs. Immunocomplexes were collected on protein A-agarose beads, washed twice with wash buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, and 10 mM MgCl2), and washed once with kinase assay buffer (10 mM Tris-HCl [pH 7.4] and 10 mM MgCl2). Wild-type or mutant GST-Rac1 recombinant proteins (2 μg) prebound to different guanine nucleotides were added to the washed immunoprecipitates, and PI3K activity was assayed by the addition of 5 μg of sonicated phosphatidylinositol and phosphatidylycerine (1:1) and 20 μM [γ-32P]ATP (200 μCi/ml) in 45 μl of kinase assay buffer. The reactions were terminated after 10 min at 25°C by the addition of 100 μl of 1 M HCl. The lipids were then immediately extracted with 200 μl of chloroform/methanol (1:1 vol/vol), and the organic phase was washed once with 80 μl of methanol/1 M HCl (1:1 vol/vol). Extracted products were submitted to TLC on potassium oxide-coated silica gel 60 plates (Merck) in a chloroform/methanol/4 M ammonium hydroxide (9:7:2 vol/vol) developing solvent. Phosphorylated products were visualized and quantified by a Fuji FLA2000 bioimaging analyzer.

To determine BCR-induced PI3K activity, DT40 cells were solubilized in lysis buffer (20 mM Tris-HCl [pH 8.0], 137 mM NaCl, 1% Triton X-100, 10% glycerol, 2 mM EDTA, 1 mM sodium vanadate, 1 mM PMSF, 1 μg/ml leupeptin, and 0.1 μg/ml aprotinin) (33), and solubilized proteins were immunoprecipitated by using anti-p85 Abs and protein A-agarose beads. Beads were washed twice with lysis buffer and washed three times with wash buffer. After wash in the kinase assay buffer, immune complexes were then subjected to PI3K assay as described above.

Results

Vav3 Is Tyrosine Phosphorylated by BCR Cross-linking. Vav3-specific antibodies were used to establish whether Vav3 is tyrosine phosphorylated after BCR engagement. Increased Vav3 phosphorylation in isolated murine B cells, as measured with anti-phosphotyrosine mAb 4G10, was apparent after 1 min of BCR stimulation, with a peak level detected 3 min after BCR cross-linking, after which phosphorylation declined (Fig. 1). These data demonstrate that Vav3, like Vav1 and Vav2 (18), is a substrate for PTKs downstream of the BCR in murine primary B cells.

Chicken DT40 B cells are a useful model for studies of BCR-mediated signal transduction; therefore, we examined whether chicken Vav3 also underwent tyrosine phosphorylation in DT40 B cells. As shown in Fig. 1, BCR stimulation of DT40 B cells resulted in a rapid increase in Vav3 phosphorylation, although the kinetics differed from those of murine primary B cells. Vav3 tyrosine phosphorylation was already maximal at 1 min, after which phosphorylation gradually declined to a lower level.

Role of Vav3 in BCR Signaling. To elucidate the function of Vav3, we established Vav3-deficient DT40 lines by the gene-targeting method (see Materials and Methods). Lack of Vav3 expression was verified by Western blot analysis (Fig. 2 A). The level of cell surface expression of BCR on Vav3-deficient DT40 cells was essentially the same as that on parental DT40 cells (Fig. 2 B). Little change of the BCR-induced overall tyrosine phosphorylation was detected between wild-type and Vav3-deficient DT40 cells (data not shown), suggesting that the BCR-associated PTKs such as Lyn and Syk are activated normally in the absence of Vav3.

![Figure 1](image-url)
One of the hallmarks of BCR-mediated signaling is the mobilization of intracellular calcium ([Ca$^{2+}$]). Indeed, calcium flux has been implicated in B cell maturation and immune responses (21, 34). Therefore, we measured BCR-induced calcium mobilization in wild-type and Vav3-deficient B cells. As shown in Fig. 3 A, the peak height of the [Ca$^{2+}$]$_{i}$ increase upon receptor stimulation was decreased by $\approx$50% by loss of Vav3. This decrease in Vav3-deficient cells, compared with wild-type cells, was still observed when extracellular Ca$^{2+}$ was chelated with EGTA, suggesting the impairment of calcium release from intracellular stores. In addition, these mutant cells exhibited reduced BCR-mediated IP$_{3}$ generation (Fig. 3 B). Together, we conclude that the calcium defect in Vav3-deficient DT40 B cells is, at least partly, due to insufficient PLC-$\gamma2$ activation. Normal calcium mobilization as well as IP$_{3}$ generation was restored by transfection of wild-type Vav3 cDNA (data not shown).

Figure 2. Generation of Vav3- and PI3K p110$\alpha$-deficient DT40 B cells. (A) Cell lysates were separated on 7.5% SDS-PAGE and analyzed by Western blotting with anti-Vav3 Abs (left) or anti-p110$\alpha$ Abs (right). (B) Cell surface expression of BCR on wild-type and mutant DT40 cells used in this study: wt, parental DT40 cells; Vav3$^{-}$, Vav3-deficient cells; p110$\alpha^{-}$, p110$\alpha$-deficient cells; wt/Vav3$^{-}$, Vav3-deficient cells expressing wild-type Vav3; mGEF/Vav3$^{-}$, Vav3-deficient cells expressing GEF mutant Vav3; Vav2/Vav3$^{-}$, Vav3-deficient cells overexpressing Vav2; SHIP$^{-}$, SHIP-deficient cells; Vav3$^{-}$/SHIP$^{-}$, Vav3/SHIP double-deficient cells; Rac1DN, cells expressing dominant negative Rac1 (Rac1N17); Btk-T7, cells expressing Btk-T7; Btk-T7/Vav3$^{-}$, Vav3-deficient cells expressing Btk-T7. Unstained cells were used as negative controls (dotted line).

Figure 3. Characterization of Vav3- and PI3K p110$\alpha$-deficient DT40 B cells. Cells were stimulated with M4 (4 $\mu$g/ml) for indicated time periods and then subjected to the following analyses. (A) Calcium mobilization. Intracellular free calcium levels in Fura-2-loaded cells were monitored by a fluorescence spectrophotometer. Calcium release from intracellular calcium stores was measured in the presence of 1 mM EGTA (dotted line). wt, wild-type. (B) IP$_{3}$ generation. Soluble IP$_{3}$ was extracted from $2 \times 10^6$ cells and subjected to a Biotrak competitive binding assay system. The results ($2 \times 10^6$ cell equivalents per point) were shown by mean $\pm$ standard error of three independent experiments. (C) Tyrosine phosphorylation of PLC-$\gamma2$. Immunoprecipitation (IP) was performed with anti-PLC-$\gamma2$ Abs. The blots (5 $\times$ 10$^5$ cell equivalents per lane) were stained with 4G10 mAb (top). The blots were stripped and reprobed with anti-PLC-$\gamma2$ Abs (bottom). (D) BCR-induced PLC-$\gamma2$ activation. PLC-$\gamma2$ was immunoprecipitated from lysates (2 $\times$ 10$^5$ cell equivalents per point), and in vitro phospholipase activity was measured as described in Materials and Methods. The results were shown by mean $\pm$ standard error of three independent experiments. (E) BCR-induced JNK1 activation. Lysates from $5 \times 10^6$ cells were immunoprecipitated with anti-JNK1 mAb, and the resulting immunoprecipitates were divided. Half of them was used for Western blot analysis using anti-JNK1 mAb (top). The remaining half was used for in vitro kinase assay using GST-c-Jun as an exogenous substrate. The kinase reaction products were resolved on 12.5% SDS-PAGE, and their phosphorylation was quantified by autoradiography (top).
Previous studies including ours showed that B cells, when treated with PI3K inhibitors such as wortmannin, manifested the partial defects in calcium mobilization and IP3 generation (31, 35–37). To formally demonstrate the resemblance of the defects between Vav3- and PI3K-deficient B cells, we took a genetic approach, as the PI3K inhibitors are known to inhibit other lipid metabolizing enzymes, in addition to PI3K (38). Heterodimer-type (class Ia) PI3Ks consist of a regulatory subunit (p85) and a catalytic subunit (p110) encoded by three distinct genes (p110α, p110β, and p110δ; reference 39). Among three p110 isoforms, p110α was dominantly expressed in DT40 B cells, as determined by Northern blot analysis (data not shown). Thus, we established p110α-deficient DT40 B cells (Fig. 2, A and B) and characterized them. In fact, both calcium mobilization and IP3 generation were partially inhibited in p110α-deficient cells (Fig. 3, A and B). Moreover, in contrast to wild-type cells, p110α- and Vav3-deficient B cells exhibited a reduction in both PLC-γ2 tyrosine phosphorylation and its in vitro lipase activity upon receptor cross-linking (Fig. 3, C and D). Further resemblance was observed in BCR-mediated JNK1 response; in vitro kinase assay revealed attenuated JNK1 activation in both p110α- and Vav3-deficient cells (Fig. 3 E).

Vav3 Regulates PI3K Activation through Rac1. The above results suggest that Vav3 and PI3K p110α influence each other’s functions or that these two molecules function independently, thereby contributing to downstream responses. To test these possibilities, we first determined whether Vav3 modulated PI3K activation in BCR signaling. As demonstrated in Fig. 4 A, BCR-mediated PIP3 generation was attenuated by ∼25% in Vav3-deficient cells, while this attenuation was ∼30% in p110α-deficient cells. As expected, inhibition extents of Akt activation in Vav3- and p110α-deficient B cells correlated well with those of PIP3 generation (Fig. 4 B). A previous study proposed the possibility that Vav1 is involved in PIP2 synthesis by stimulating PIP 5-kinase (40). As PIP2 is a substrate for PI3K, attenuation of PIP3 generation in Vav3-deficient cells might be similarly accounted for by insufficient replenishment of PIP2 rather than by insufficient PIP3 synthesis. However, this possibility is unlikely in DT40 B cells, because we could not detect significant differences of PIP2 levels between wild-type and Vav3-deficient cells during the course of BCR stimulation (Fig. 4 C). Therefore, we conclude that Vav3 regulates PI3K activation in DT40 B cells. PIP3 is thought to be involved in PLC-γ2 activation through its binding to the Btk PH domain and its subsequent activation (31, 37). Hence, our conclusion is further supported by the observation that BCR-mediated tyrosine phosphorylation of Btk was significantly reduced in Vav3-deficient cells (Fig. 4 D).

As predicted, BCR-mediated Rac1 activation, as measured by a Pak-binding assay, was attenuated by ∼50% in Vav3-deficient DT40 cells (Fig. 5 B). Introduction of wild-type Vav3, but not its GEF mutant, into Vav3-deficient cells restored Rac1 activation. Moreover, BCR-mediated Akt activation was restored only by wild-type Vav3 (Fig. 5 C).

![Figure 4](image-url)
C). Then, to formally demonstrate that the effect of Vav3 on PI3K is indeed mediated by Rac1, we examined DT40 cells expressing a dominant-negative form of Rac1, Rac1N17 (Fig. 5 A; reference 20). The transfected cells exhibited attenuation of both PIP3 generation (Fig. 4 A) and Akt activation upon BCR engagement (Fig. 5 D).

**Rac1 Stimulates PI3K Activity in a GTP-dependent Manner.** Optimal PI3K activation is thought to require at least two events in the context of antigen receptor signaling: (a) recruitment of PI3K to the plasma membrane, particularly to GEMs (41–43); (b) an increase in the PI3K enzymatic activity by its conformational change (44). To obtain more insight into how Vav3 affects PI3K activation in BCR signaling, we studied whether these two events were modulated by Vav3-dependent Rac1 activation. First, we compared BCR-mediated recruitment of PI3K p85 subunit to GEMs in wild-type and Vav3-deficient cells, revealing no differences (Fig. 6).

In vitro kinase experiments were employed to examine the second possibility. Anti-p85 immunoprecipitates from 293T cells transfected with both PI3K p85α and p110α subunits were mixed with different guanine nucleotide-bound forms of GST–Rac1 and subjected to a PI3K enzymatic assay. Consistent with a previous report (45), the GTP-bound GST–Rac1 stimulated PI3K activity about threefold, while GDP-bound GST–Rac1 stimulated the PI3K activity by 1.2-fold (Fig. 7 A). As a negative control, immunoprecipitates from 293T cells expressing wild-type p85α and kinase-negative p110α were used, showing undetectable levels of in vitro PI3K activity in our assay conditions. Proper expression and association of these two subunits were verified by Western blot analysis (Fig. 7 B). The biological relevance of the above findings with 293T cells was examined by precipitating PI3K from resting and stimulated DT40 B cells and measuring its in vitro kinase activity. As shown in Fig. 7 C, Vav3–deficient B cells exhibited reduced PI3K activation, and this defect was restored by wild-type Vav3, but not its GEF mutant. Taken together, these findings suggest that Rac1, after being activated by Vav3, contributes to enzymatic activation of PI3K rather than to its recruitment to GEMs.

**BCR-mediated Tyrosine Phosphorylation of Vav3 Occurs Normally in the Absence of PI3K p110α.** Previous in vitro studies place Vav1 downstream of PI3K; PIP3 binds to the Vav1 PH domain and promotes tyrosine phosphorylation-mediated activation of the enzymatic activity of Vav1 (7). To determine whether PI3K similarly modulates Vav3 activation, we assessed Vav3 tyrosine phosphorylation and subsequent Rac1 activation using p110α-deficient DT40 cells. As shown in Fig. 8, significant changes in both parameters in wild-type versus mutant DT40 cells could not be detected, except a small decrease of Vav3 tyrosine phosphorylation after 10 min stimulation in p110α-deficient cells. These readouts could not be affected in DT40 B cells, even when treated with 100 nM wortmannin.

---

**Figure 5.** Vav3 regulates BCR-mediated Akt response through Rac1. (A) Expression levels of wild-type (wt) or GEF mutant Vav3 in Vav3-deficient DT40 cells (left) or of Myc-tagged dominant-negative Rac1 in wild-type DT40 cells (right). Whole-cell lysates were analyzed by Western blotting using anti-Vav3 Abs (left) or anti-Rac1 mAb (right). (B) Rac1 activation in response to BCR cross-linking. Cells (5 × 10⁶) were stimulated with M4 (4 μg/ml), and cell lysates were mixed with beads containing the CRIB of PAK. Elutes of the beads (top) or cell lysates (bottom) were resolved on 12.5% SDS-PAGE and subjected to Western blot analysis with anti-Rac1 mAb. AP, affinity precipitation. (C and D) Effects of mutations of Vav3 and Rac1 on Akt responses. Cells were stimulated with M4 (4 μg/ml) for indicated times. Cell lysates were subsequently subjected to in vitro kinase assay of Akt, as described in the legend to Fig. 4 B. IP, immunoprecipitation.

**Figure 6.** Inactivation of Vav3 does not affect PI3K recruitment to glycolipid-enriched microdomains (GEMs). Wild-type (wt) and Vav3-deficient DT40 cells (10⁶ cells per condition), unstimulated (minus symbol) or stimulated with M4 (4 μg/ml) for 1 min (plus symbol), were lysed and then subjected to discontinuous sucrose density gradient centrifugation. Fractions (30 μl/lane, numbered from low to high density) were resolved on 7.5% SDS-PAGE and immunoblotted with anti-p85 Abs or anti-Lyn Abs. Lyn was used as a positive control for GEM fraction.
Deletion of SHIP Suppresses Defects in Vav3-deficient Cells. Collectively, the above data suggest that Vav3 functions upstream of PI3K activation, thereby contributing to calcium mobilization and JNK1 activation. This hypothesis predicts that defects in Vav3-deficient DT40 cells should be suppressible by manipulations which enhance PIP3 accumulation. To test this prediction, we deleted a PIP3-hydrolyzing enzyme, SHIP, in a Vav3-deficient background. As shown in Fig. 9, both of these defects, in addition to downmodulation of Akt in Vav3-deficient cells, were relieved by deletion of SHIP. Hence, reduction in PIP3 levels likely results in inhibition of calcium mobilization as well as JNK1 activation in Vav3-deficient cells.

Overexpression of Vav2 Rescues Defects in Vav3-deficient Cells. Although we cloned chicken homologs of Vav2 and Vav3, Vav1 isoform could not be detected in spite of our several efforts including low-stringency cross-hybridization, degenerative-oligonucleotide reverse transcription (RT)-PCR, and EST database search. Given the evidence that Vav2, like Vav3, undergoes tyrosine phosphorylation after BCR cross-linking in DT40 B cells (data not shown), Vav2 could have overlapping functions with those of Vav3. If so, we speculate that Vav2, once overexpressed in a Vav3-deficient background, can compensate some functional defects of Vav3-deficient DT40 B cells. To examine this possibility, we established Vav3-deficient cells that expressed fourfold higher level of Vav2 than that in wild-type cells. As shown in Fig. 10, defects in Rac1, Akt, and calcium responses were compensated by overexpression of Vav2, suggesting the existence of some functional redundancy between Vav2 and Vav3.

Discussion

Vav1 and Vav2 play an important role in coupling BCR to calcium flux (16, 17). Here we extended this concept to show that Vav3, like Vav1 and Vav2, participates in calcium mobilization. Then, we addressed the mechanisms by which Vav3 influences the calcium flux. Many aspects of PLC-γ2/calcium defects are similar in Vav3-deficient and PI3K p110α-deficient DT40 B cells. For instance, BCR-mediated PLC-γ2 tyrosine phosphorylation and subse-
quent IP3 generation are similarly attenuated in both backgrounds (Fig. 3, B and C), thereby prompting us to examine the relationship between Vav3 and PI3K. Previous in vitro studies favor the model that PI3K functions upstream of Vav as regulators of GEF activity (7). Our data instead support a different mechanism, in which Vav3 functions as a positive regulator of PI3K in BCR signaling.

We demonstrate that BCR-mediated PIP3 generation and subsequent Akt activation are inhibited by loss of Vav3 (Fig. 4, A and B) or by introduction of Rac1N17 into DT40 B cells (Figs. 4 A and 5 D). Strengthening the idea that Vav3-mediated Rac1 activation is involved in PIP3 generation, a Vav3 GEF mutant fails to restore Rac1 activation as well as PI3K activation (Figs. 5 B and 7 C). Hence, the results presented here are consistent with reports that, in Jurkat T cells and RBL mast cells, Akt activation is blocked by overexpression of dominant negative Rac1 and by treatment of Clostridium sordellii lethal toxin, a Rac-inactivating toxin, respectively (46, 47). The inhibition of PIP3 generation in Vav3-deficient cells could be accounted for by the decreased availability of a PI3K substrate, PIP2, and/or by the decreased PIP3 synthesis from PIP2. Two lines of our evidence suggest that the latter mechanism is dominantly operating in DT40 B cells. First, overall PIP2 levels are not significantly changed between wild-type and Vav3-deficient DT40 B cells (Fig. 4 C). Second, the enzymatic activity of PI3K, a responsible kinase for PIP3 synthesis, is indeed increased by Rac1 in a GTP-dependent manner (Fig. 7 A). However, the former mechanism cannot be completely excluded by our data. Recent studies showed that PI3K activation occurs in subdomains of the plasma membrane, called GEMs or lipid rafts (42), suggesting that PIP3 localized specifically in GEMs serves as a PI3K substrate in BCR signaling context. In this regard, our overall PIP2 assay system might not have sufficed enough to detect small changes in the level of PIP2 which reside in GEMs.

Based on the in vitro data that PIP3 binds to the Vav1 PH domain and promotes PTK-mediated activation of its GEF activity, PI3K has been proposed to function as an upstream regulator for Vav family members (7). Hence, our finding that Vav3 is involved in PI3K activation implies two possibilities; (a) in addition to regulation of PI3K by Vav3, PI3K could reciprocally influence Vav3 function,
...theory of the negative feedback control mechanism that could be required for efficient PIP3 generation. Our data support this possibility. Deletion of PI3K p110α affects neither Vav3 tyrosine phosphorylation nor Rac1 activation. In addition, as reported previously in FcεRI signaling (47), these readouts could not be affected in DT40 B cells, even when PI3K generation was almost completely inhibited by wortmannin (Fig. 8A and B). However, given the evidence that PIP3 cannot activate nonphosphorylated Vav1 (7), one interpretation for our results is that a role of PIP3 is the fine modulation of the enzyme activity of Vav3 only after being phosphorylated, rather than as a critical Vav3 regulator. This fine modulation by PIP3 might have escaped detection in our experimental conditions.

Activation of PI3K upon BCR engagement is thought to involve recruiting PI3K to GEMs as well as increasing the specific activity of the enzyme. BCRI-induced translocation of PI3K to GEMs occurs normally in Vav3-deficient DT40 cells (Fig. 6), which suggests that other molecules play a major role in PI3K recruitment to GEMs, whereas Vav3 participates in upregulation of the PI3K enzymatic activity. Like PI3K, Vav3 is also targeted to GEMs after receptor cross-linking (data not shown), thereby being able to gain access to its substrate Rac1, as Rac1 is known to be concentrated in GEMs (48). Subsequently, PI3K is activated by GTP-bound Rac1. In regard to recruitment of PI3K to GEMs, docking proteins such as CD19, Gab, and BCAP could participate in this process, directly or indirectly, because these proteins, after being tyrosine phosphorylated, associate with the SH2 domains of the PI3K p85 subunit (27, 49–52). Colocalization of Vav3 and PI3K in GEMs appears to be necessary, but their mere colocalization in GEMs might not be sufficient for PIP3 generation. For instance, when CD19 is tyrosine phosphorylated upon BCR ligation alone or coligation of BCR and CD19, the phosphorylated CD19 provides binding sites for both Vav1 and PI3K (51, 53). Assuming that Vav3, like Vav1, is recruited to the phosphorylated CD19, CD19 can bring Vav3 and PI3K into the close proximity with each other, which in turn, could facilitate the efficient coupling between Vav3 and PI3K in B cells. Thus, an organized multi-protein complex including Vav3 and PI3K in GEMs may be required for efficient PIP3 generation.

The reduced PLC-γ2 activation in Vav3-deficient DT40 B cells after BCR engagement could be accounted for by the decreased PI3K activation. In support of this explanation, the PLC-γ2/calcium defects in Vav3-deficient B cells are relieved by deletion of a PIP3 hydrolizing enzyme, SHIP. In fact, consistent with a previous report using SHIP−/− primary B cells (54), PIP3 levels upon BCR activation are increased in SHIP-deficient DT40 B cells (Fig. 4A). PIP3 is thought to function as a positive regulator of PLC-γ2 via two distinct mechanisms. One mechanism is that PIP3 is involved in PLC-γ2 activation through its binding to the Btk PH domain and its subsequent activation (31, 37), as Btk is essential for PLC-γ2 activation upon BCR engagement. In this regard, we observed reduced BCR-mediated tyrosine phosphorylation of Btk in Vav3-deficient DT40 cells, compared with wild-type cells (Fig. 4D). The second mechanism is that the PLC-γ2 PH domain binds to PIP3, which in turn contributes to PLC-γ2 activation by its targeting to GEMs and/or by its conformational changes (55–57). Although it is clear that PIP3-mediated PLC-γ2 activation contributes to calcium mobilization, this mechanism may not entirely account for the effect of Vav3 on calcium mobilization. For example, activated Rac1 could directly modulate a calcium influx channel on the plasma membrane (58), in addition to activating PI3K.

Given our previous evidence that calcium mobilization, in addition to Rac1 activation, is required for coupling BCR to JNK1 (20, 22), the reduced activation of JNK1 in Vav3-deficient cells could be explained, at least in part, by the insufficient calcium mobilization. Indeed, Vav3/SHIP double-deficient DT40 B cells exhibit augmentation in both calcium mobilization and JNK1 activation (Fig. 9, A and B). Thus, it is reasonable to anticipate that Rac1 regulates MAP3K as well as PLC-γ2, both of which contribute to the optimal JNK1 response in the BCR signaling context.

Although this study has not addressed the functional differences among Vav isoforms, our results demonstrate that Vav2, when overexpressed, can compensate for Vav3-regulated Rac1 activation and calcium flux in B cells. Thus, given the previous evidence that both Vav1 and Vav2 are able to augment calcium flux and NF-AT activation in B cell lines (18), we suggest that all three Vav isoforms possess overlapping functions in BCR signaling. Consistent with this, mice deficient in Vav1 or Vav2 show a modest defect in calcium mobilization in response to BCR cross-linking, whereas this defect is exaggerated in mice lacking both Vav1 and Vav2 (16, 17). Hence, the mechanism we have described for Vav3 in chicken B cells is likely to be applicable to other Vav isoforms in the B cell context. Indeed, in agreement with our conclusion, recent works from other groups have shown that Vav1 could also regulate antigen receptor-induced PI3K activation in murine mast cells (15) and thymocytes (unpublished data).

Our implications, however, do not invalidate the previous contention that each Vav isoform has an unique function in other cell types. For instance, T cell studies demonstrate that Vav1 and Vav3 are not simply interchangeable in that overexpression of Vav1, but not Vav3, potentiates TCR-mediated NF-AT activation (59). Considering that Vav family proteins must associate with adaptor molecules for exerting their functions, the inability of Vav3 to induce calcium signaling in T cells may be due to its insufficient interaction with adaptor molecules such as SLP-76 (60). In contrast, BLNK and CD19 in B cells may interact with Vav3 and Vav1 with the same efficiency (40, 51, 53, 61, 62). Differences in the substrate specificity of the Rho family GTPases between Vav1 and Vav3 could be another possibility. High preference of Vav1 toward Rac1 might be required for T cells to activate calcium signaling. Thus, each Vav isoform, like Vav1, has GEF-dependent and -independent functions (23), both of which coordinately contribute...
to signal transduction pathways, depending upon differential cellular contexts.

We would like to thank Drs. P.K. Vogt, M.D. Waterfield, A. Weiss, and R. Goitsuka for providing chicken p110α cDNA, bovine p85α cDNA, human Vav1 and Vav2 cDNAs, and DT40 cDNA library, respectively. We also thank Drs. V.L.J. Tybulewicz and L.F. Reynolds for advice on the PI3K determination, Drs. A. Weiss and G.M. Ku for advice on the Rac1/PAK pull-down assay, Dr. D. Watanabe for advice on the phospholipid hydrolyzing assay, Dr. M. Turner for helpful discussions, and M. Takezaki, and N. Narumi for technical assistance.

This work was supported by grants from the Ministry of Education, Science, Sports, and Culture of Japan (to K. Inabe, M. Ishiai, and T. Kurosaki), the Uehara Memorial Foundation (to T. Kurosaki), and the Human Frontier Science Program (to T. Kurosaki).

Submitted: 10 September 2001
Revised: 16 November 2001
Accepted: 30 November 2001

References
1. DeFranco, A.L. 1997. The complexity of signaling pathways activated by the BCR. *Curr. Opin. Immunol.* 9:296–308.
2. Reth, M., and J. Wienands. 1997. Initiation and processing of signals from the B cell antigen receptor. *Annu. Rev. Immunol.* 15:453–479.
3. Tamir, I., and J.C. Cambier. 1998. Antigen receptor signaling: integration of protein tyrosine kinase functions. *Oncogene.* 17:1353–1364.
4. Kurosaki, T. 1999. Genetic analysis of B cell antigen receptor signaling. *Annu. Rev. Immunol.* 17:555–592.
5. Bustelo, X.R. 2000. Regulatory and signaling properties of the Vav family. *Mol. Cell. Biol.* 20:1461–1477.
6. Crespo, P., K.E. Schuebel, A.A. Ostrom, J.S. Gutkind, and X.R. Bustelo. 1997. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. *Nature.* 385:169–172.
7. Han, J., K. Luby-Phelps, B. Das, X. Shu, Y. Xia, R.D. Moskowitz, U.M. Krishna, J.R. Falck, M.A. White, and D. Broek. 1998. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. *Science.* 279:558–560.
8. Bustelo, X.R., S.D. Rubin, K.L. Suen, D. Carrasco, and M. Barbacid. 1993. Developmental expression of the vav proto-oncogene. *Cell. Growth Differ.* 4:297–308.
9. Schuebel, K.E., X.R. Bustelo, D.A. Nielsen, B.J. Song, M. Barbacid, D. Goldman, and I.J. Lee. 1996. Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes. *Oncogene.* 13:363–371.
10. Movilla, N., and X.R. Bustelo. 1999. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. *Mol. Cell. Biol.* 19:7870–7885.
11. Zeng, L., P. Sachdev, L. Yan, J.L. Chan, T. Trenkle, M. McClelland, J. Welsh, and L.H. Wang. 2000. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. *Mol. Cell. Biol.* 20:9212–9224.
12. Tarakhovsky, A., M. Turner, S. Schaal, P.J. Mee, L.P. Duddy, K. Rajewsky, and V.L. Tybulewicz. 1995. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. *Nature.* 374:467–470.
13. Zhang, R., F.W. Alt, L. Davidson, S.H. Orkin, and W. Swat. 1995. Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. *Nature.* 374:470–473.
14. Fischer, K.D., A. Zmuldzinas, S. Gardner, M. Barbacid, A. Bernstein, and C. Guidos. 1995. Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes. *Nature.* 374:474–477.
15. Manetz, T.S., C. Gonzalez-Espinosa, R. Arudchandran, S. Xirasagar, V. Tybulewicz, and J. Rivera. 2001. Vav1 regulates phospholipase Cγ activation and calcium responses in mast cells. *Mol. Cell. Biol.* 21:3763–3774.
16. Doody, G.M., S.E. Bell, E. Vigorito, E. Clayton, S. McAdam, R. Tooze, C. Fernandez, I.J. Lee, and M. Turner. 2001. Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. *Nat. Immunol.* 2:542–547.
17. Tedford, K., L. Nitschke, I. Girkontaite, A. Charlesworth, G. Chan, V. Sakk, M. Barbacid, and K.D. Fischer. 2001. Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. *Nat. Immunol.* 2:548–555.
18. Doody, G.M., D.D. Billadeau, E. Clayton, A. Hutchings, R. Berland, S. McAdam, P.J. Leibson, and M. Turner. 2000. Vav-2 controls NFAT-dependent transcription in B- but not T-lymphocytes. *EMBO J.* 19:6173–6184.
19. Okada, H., S. Bolland, A. Hashimoto, M. Kurosaki, Y. Kabuyama, M. Inoue, J.V. Ravetch, and T. Kurosaki. 1998. Role of the insulin phosphate SHIP in B cell receptor-induced Ca2+ oscillatory response. *J. Immunol.* 161:5129–5132.
20. Hashimoto, A., H. Okada, A. Jiang, M. Kurosaki, S. Greenberg, E.A. Clark, and T. Kurosaki. 1998. Involvement of guanosine triphosphatases and phospholipase C-γ2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. *J. Exp. Med.* 188:1287–1295.
21. Hashimoto, A., K. Takeda, M. Inaba, M. Sekimata, T. Kashiho, S. Ikehara, Y. Homma, S. Akira, and T. Kurosaki. 2000. Cutting edge: essential role of phospholipase C-γ2 in B cell development and function. *J. Immunol.* 165:1738–1742.
22. Ishiai, M., M. Kurosaki, R. Pappu, K. Okawa, I. Ronko, C. Fu, M. Shibata, A. Iwamatsu, A.C. Chan, and T. Kurosaki. 1999. BLNK required for coupling Syk to PLCγ2 and Rac1-JNK in B cells. *Immunol. 10:117–125.
23. Kuhne, M.R., G. Ku, and A. Weiss. 2000. A guanine nucleotide exchange factor-independent function of Vav1 in transcriptional activation. *J. Biol. Chem.* 275:2185–2190.
24. Takata, M., H. Sabe, A. Hata, T. Inazu, Y. Homma, T. Nakuda, H. Yamamura, and T. Kurosaki. 1994. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. *EMBO J.* 13:1341–1349.
25. Kurosaki, T., and M. Kurosaki. 1997. Transphosphorylation of Bruton’s tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. *J. Biol. Chem.* 272:15595–15598.
26. Yasuda, T., A. Maeda, M. Kurosaki, T. Tezuka, K. Hironaka, T. Yamamoto, and T. Kurosaki. 2000. Cbl suppresses B cell receptor-mediated phospholipase C (PLC)-γ2 activation by regulating B cell linker protein-PLC-γ2 binding. *J. Exp. Med.* 191:641–650.
27. Okada, T., A. Maeda, A. Iwamatsu, K. Gotoh, and T. Kurosaki.
28. Watanabe, D., X. Zhao, X.Q. Chen, L. Tan, I. Tan, T. Leung, and L. Lim. 1998. PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. Mol. Cell. 1:183–192.

30. Ishiai, M., M. Kurosaki, K. Inabe, A.C. Chan, K. Sugamura, and T. Kurosaki. 2000. Involvement of LAT, Gads, and Grb2 in compartmentation of SLIP-76 to the plasma membrane. J. Exp. Med. 192:847–856.

32. Hippen, K.L., A.M. Buhl, D. D’Ambrosio, K. Nakamura, C. Z. S. Zhao, X. Q. Chen, L. Hippen, K.L., A.M. Buhl, D. D’Ambrosio, K. Nakamura, C. Zhang, R.P. Siraganian, U. Blank, and J. Rivera. 2000. The Src homology 2 domain of Vav is required for its compartmentation to the plasma membrane and activation of c-Jun NH2-terminal kinase 1. J. Exp. Med. 191:47–60.

34. Buhl, A.M., C.M. Pleiman, R.C. Rickert, and J.C. Cambier. 1999. Qualitative regulation of B cell antigen receptor signaling by CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase. Mol. Cell. Biol. 20:5469–5478.

36. Zheng, Y., S. Bagrodia, and R.A. Cerione. 1994. Activation of phosphoinositide 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol. Cell. Biol. 16:4117–4127.

42. Gillham, H., M.C. Golding, R. Pepperkok, and W.J. Gulllick. 1999. Intracellular movement of green fluorescent protein-tagged phosphatidylinositol 3-kinase in response to growth factor receptor signaling. J. Cell Biol. 146:869–880.

44. Shoelson, S.E., M. Sivaraja, K.P. Williams, P. Hu, J. Schlessinger, and M.A. Weiss. 1993. Specific phosphopeptidase binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation. EMBO J. 12:795–802.

52. Gold, M.R. 2000. Intermediary signaling effectors coupling the B-cell receptor to the nucleus. Curr. Top. Microbiol. Immunol. 245:77–134.
and S.G. Rhee. 1998. Activation of phospholipase C-γ by phosphatidylinositol 3,4,5-trisphosphate. *J. Biol. Chem.* 273: 4465–4469.

58. Djouder, N., U. Prepens, K. Aktories, and A. Cavalie. 2000. Inhibition of calcium release-activated calcium current by Rac/Cdc42-inactivating clostridial cytotoxins in RBL cells. *J. Biol. Chem.* 275:18732–18738.

59. Moores, S.L., L.M. Selfors, J. Fredericks, T. Breit, K. Fujikawa, F.W. Alt, J.S. Brugge, and W. Swat. 2000. Vav family proteins couple to diverse cell surface receptors. *Mol. Cell. Biol.* 20:6364–6373.

60. Wu, J., D.G. Motto, G.A. Koretzky, and A. Weiss. 1996. Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation. *Immunity.* 4:593–602.

61. Fu, C., C.W. Turck, T. Kurosaki, and A.C. Chan. 1998. BLNK: a central linker protein in B cell activation. *Immunity.* 9:93–103.

62. Wienands, J., J. Schweikert, B. Wollscheid, H. Jumaa, P.J. Nielsen, and M. Reth. 1998. SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation. *J. Exp. Med.* 188:791–795.